8 completed, 2 terminated. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 2 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow MorphoSys AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| MOR202 for Refractory MN MOR202 - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2021-10-22 | 2026-07-13 |
| Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Tafasitamab, Idelalisib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia | Phase 2 | Completed | MorphoSys AG | 24 | 2016-11-01 | 2021-12-20 |
| Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Tafasitamab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | MorphoSys AG | 81 | 2016-03-29 | 2023-10-23 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) MOR00208 (formerly Xmab 5574) - Non-Hodgkin Lymphoma | Phase 2 | Completed | MorphoSys AG | 92 | 2013-04-23 | 2023-11-07 |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) MOR00208 (formerly Xmab5574) - Acute Lymphoblastic Leukemia | Phase 2 | Terminated | MorphoSys AG | 22 | 2013-04-01 | 2018-02-22 |
| Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis MOR103, Placebo - Multiple Sclerosis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 32 | 2012-01-01 | 2014-11-21 |
| A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | MorphoSys AG | 91 | 2011-07-01 | 2021-11-16 |
| Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis MOR103 - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 96 | 2009-12-01 | 2014-10-24 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Arthritis, Rheumatoid (1) · Burkitt Lymphoma (1) · Glomerulonephritis, Membranous (1) · Leukemia, Prolymphocytic (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Multiple Sclerosis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
tafasitamab (6) · Lenalidomide (4) · Otilimab (2) · felzartamab (2) · Dexamethasone (1) · idelalisib (1) · pomalidomide (1) · venetoclax (1)
Germany (6) · United States (6) · Poland (5) · Italy (4) · United Kingdom (3) · Austria (2) · Belgium (2) · Hungary (2) · Spain (2) · Bulgaria (1) · Czechia (1) · France (1) · Japan (1) · Netherlands (1) · South Korea (1)
Roman P Korolkiewicz, MD, PhD (2) · Anke Muth (1) · Elias Jabbour, MD (1) · Giuseppe Remuzzi, MD (1) · Jennifer Woyach, MD (1) · Johannes Duell, MD (1) · Rebecca Klisovic, MD (1) · Wing H. Leung, M.D., PhD (1)
PMID 24534756, PMID 29444231, PMID 32171061, PMID 32511983, PMID 34196165, PMID 34343354, PMID 34414843, PMID 34433649, PMID 34779360, PMID 35674661, PMID 35861632, PMID 37646664, PMID 42027554
2014 (1)